Sanofi - ADR (SNY): Price and Financial Metrics
SNY Price/Volume Stats
|Current price||$46.72||52-week high||$57.82|
|Prev. close||$46.75||52-week low||$42.63|
|Day high||$46.86||Avg. volume||1,738,458|
|50-day MA||$49.82||Dividend yield||2.93%|
|200-day MA||$51.91||Market Cap||118.18B|
SNY Stock Price Chart Interactive Chart >
Sanofi - ADR (SNY) Company Bio
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.
SNY Latest News Stream
|Loading, please wait...|
SNY Latest Social Stream
View Full SNY Social Stream
Latest SNY News From Around the Web
Below are the latest news stories about SANOFI that investors may wish to consider to help them evaluate SNY as an investment opportunity.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,036,828 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi
Pharmaceutical companies are currently developing vaccines for a range of purposes, from preventing disease to treating cancers.
In this article, we will look into the 20 most valuable healthcare companies in the world. If you want to skip our detailed analysis, you can go directly to the 5 Most Valuable Healthcare Companies in the World. Healthcare Services Industry: A Market Analysis According to a report by Verified Market Research, the global healthcare […]
CORRECTED-UPDATE 2-CDC expedites release of 77,000 additional doses of Sanofi-AstraZeneca's RSV drug
The U.S. Centers for Disease Control and Prevention said on Thursday it has expedited the release of more than 77,000 additional doses of Sanofi and AstraZeneca's respiratory syncytial virus (RSV) drug Beyfortus. The additional doses, which the CDC said will be distributed immediately to physicians and hospitals, will help improve the availability of the drug at a time when a surge in cases of the disease is outpacing supply.
(Bloomberg) -- Sanofi is working with an adviser to start preparations for a planned separation of its consumer health division, people with knowledge of the matter said.Most Read from BloombergHamas Chief Who Deceived Israel Is Target No. 1 Deep UndergroundBiden, Xi Declare Progress After Concluding Four-Hour SummitXi Says China Seeks to Be Friends With US, Won’t Fight ‘Hot War’Bond Yields Slide on ‘Fed-Friendly’ Economic Data: Markets WrapIsrael Latest: Biden Defends Hospital Raid, Says Hamas
SNY Price Returns
|Ex-Dividend Date||Type||Payout Amount||Change|
|Loading, please wait...|